EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026

Wednesday, November 1, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026

NEW YORK, Oct. 31, 2017 /PRNewswire/ -- SummaryCrohn's disease (CD) is an inflammatory bowel disease (IBD) characterized

by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon). The disease course of CD is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of the parts of the bowel.Read the full report: https://www.reportlinker.com/p05164804Our epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 at an Annual Growth Rate (AGR) of 0.53%. The US will have the highest number of diagnosed incident cases of CD in both 2016 and 2026 at 44,886 and 47,477, respectively.Our epidemiologists forecast that the diagnosed prevalent cases of CD in the 7MM will increase from 1,621,866 in 2016 to 1,961,224 in 2026 at an AGR of 2.09%. The US will have the highest number of diagnosed prevalent cases of CD in both 2016 and 2026; however, France will have the highest AGR at 4.04%.The report "EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and global and historical trends for CD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of CD in these markets. The diagnosed prevalent cases of CD are further segmented by sex and age in these markets. The diagnosed prevalent cases are further segmented by severity (mild to moderate, moderate to severe, and severe to fulminant) and by comorbid autoimmune diseases (psoriasis, ankylosing spondylitis, and pyodermagangrenosum).Furthermore, an alternate forecast of diagnosed incident and diagnosed prevalent cases of CD is provided for markets where there was insufficient data to trend in the main forecast, to estimate the patient size if trending was applied. For incident cases the alternate forecast includes the US and 5EU (France, Germany, Italy, Spain, and UK), and for prevalent cases the alternate forecast includes Germany, Italy, Spain, and the UK.Scope- The Crohn's Disease (CD) EpiCast Report provides an overview of the risk factors and global trends for CD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of CD in these markets. The diagnosed prevalent cases of CD are further segmented by sex and age in these markets. The diagnosed prevalent cases are further segmented by severity (mild to moderate, moderate to severe, and severe to fulminant) and by comorbid autoimmune diseases (psoriasis, ankylosing spondylitis, and pyoderma gangrenosum). Furthermore, an alternate forecast of diagnosed incident and diagnosed prevalent cases of CD is provided for markets where there was insufficient data to trend in the main forecast, to estimate the patient size if trending was applied.- The CD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.Reasons to buyThe CD EpiCast report will allow you to -- Develop business strategies by understanding the trends shaping and driving the global CD market.- Quantify patient populations in the global CD market to improve product design, pricing, and launch plans.- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CD therapeutics in each of the markets covered.- Understand magnitude of CD population by disease severity and comorbid autoimmune diseases.Read the full report: https://www.reportlinker.com/p05164804 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com  __________________________ Contact Clare: [email protected]  US: (339)-368-6001 Intl: +1 339-368-6001 

View original content:http://www.prnewswire.com/news-releases/epicast-report-crohns-disease---epidemiology-forecast-to-2026-300546632.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store